The Correlation Between CITED2 and Collateral Circulation in Acute Ischemic Stroke

Acute Ischemic Stroke Clinical Trial

Official title:

The Impact of CITED2 on Collateral Circulation and Early Neurological Functional Outcome for Ischemic Stroke by Critically Regulating HIF-1α-VEGF Pathway

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05345366
• Other study ID #: 2021LX0027-GC
• Status: Completed
• Start date: November 1, 2020
• Est. completion date: November 30, 2021

Study information

• Verified date: April 2022
• Source: Zhujiang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluating the collateral circulation of acute ischemic stroke (AIS) mainly depends on the imaging examination. At present, there is no effective and sensitive biomarker for collateral circulation. Thus, the research objective was to evaluate the predicting role of the CBP/P300-interacting transactivator with Glu/Asp-rich C-terminal domain 2 Ratio (CITED2) from peripheral blood mononuclear cells in the collateral circulation of AIS. We classified the AIS patients into two groups (the good collateral group and the poor collateral group) by DWI-ASPECTS score. The western blot was applied to test the protein expression of vascular endothelial growth factor (VEGF) and CITED2. Then, we collected other clinical data. Binary logistic regression analysis between collateral circulation and clinical data was performed. Finally, Receiver operating characteristic (ROC) curve analysis was used to explore the predictive value of the CITED2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: November 30, 2021
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• the first-time onset or previous stroke with mRS score =1, and the onset time less than 3 days without intravenous thrombolysis or endovascular therapy ;
• age range of 18 to 80 years old;
• patients with a clinical diagnosis of acute ischemic stroke; ? NIHSS score =4; ? patients volunteer to participate in this study and signed a written informed consent

Exclusion Criteria:

• ?the patients with AIS combined with other diseases that may affect the CITED2 and VEGF expression, such as acute myocardial infarction, peripheral artery occlusion disease and congenital heart defect;
• the patients exhibited serious heart, live or kidney diseases; ?disturbance of consciousness or mental illness; ? patients with tumor; ? pregnant and lactating patients.

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Other:
• non-applicable
non-applicable

Locations

Country	Name	City	State
China	Zhujiang Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CITED2	western blot	within 24 hours after hospitalization
Primary	VEGF	western blot	within 24 hours after hospitalization